### [Endo et al. Page 1402][1] Colorectal cancer patients with defective mismatch repair and high microsatellite instability (dMMR/MSI-H) tend to be more likely to benefit from immune checkpoint inhibitors (ICI), a finding that led to the recent FDA approval of the anti-PD-1 monoclonal antibody,

中文翻译：

---

本期精选文章

### [Endo等。Page 1402] [1]具有错配修复缺陷和高微卫星不稳定性（dMMR / MSI-H）的大肠癌患者倾向于从免疫检查点抑制剂（ICI）中获益，这一发现导致最近FDA批准了该方法。抗PD-1单克隆抗体，